Boron-based drugs as antiprotozoals

Current Opinion in Infectious Diseases

Volumn 24, Issue 6, 2011, Pages 586-592

  Jacobs, Robert T ^a   Plattner, Jacob J ^b   Keenan, Martine ^c  

^a SCYNEXIS Inc   (United States)

^b PFIZER INC   (United States)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

Benzoxaboroles; Chagas disease; Human african trypanosomiasis; Malaria; Neglected tropical diseases

Indexed keywords

ANTIPROTOZOAL AGENT; BENZNIDAZOLE; BENZOXABOROLE; BORON DERIVATIVE; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG STABILITY; GASTROINTESTINAL DISEASE; HUMAN; MALARIA; NEUROPATHY; NONHUMAN; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PRODUCT DEVELOPMENT; REVIEW; TROPICAL DISEASE;

ANTIMALARIALS; ANTIPROTOZOAL AGENTS; BORON COMPOUNDS; CHAGAS DISEASE; HUMANS; MALARIA; TRYPANOSOMIASIS, AFRICAN;

EID: 80055011837     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834c630e     Document Type: Review

References (40)

1. Mahmoud A, Zerhouni E. Neglected tropical diseases: moving beyond mass drug treatment to understanding the science. Health Aff (Millwood) 2009; 28:1726-1733.
2. Croft SL. Neglected diseases: progress in drug development. Curr Opin Investig Drugs 2007; 8:103-104. (Pubitemid 46438463)
3. Renslo AR, McKerrow JH. Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2006; 2:701-710. (Pubitemid 44764212)
4. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-126. (Pubitemid 43157649)
5. Robays J, Lefevre P, Lutumba P, et al. Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Trop Med Int Health 2007; 12:290-298.
6. Yun O, Priotto G, Tong J, et al. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 2010; 4:e720.
7. Dembitsky VM, Quntar AA, Srebnik M. Recent advances in the medicinal chemistry of alpha-aminoboronic acids, amine-carboxyboranes and their derivatives. Mini Rev Med Chem 2004; 4:1001-1018. (Pubitemid 39406259)
8. Hunter P. Not boring at all. Boron is the new carbon in the quest for novel drug candidates. EMBO Rep 2009; 10:125-128.
9. Baker SJ, Tomsho JW, Benkovic SJ. Boron-containing inhibitors of synthetases. Chem Soc Rev 2011; 40:4279-4285.
10. Baker SJ, Zhang YK, Akama T, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 2006; 49:4447-4450. (Pubitemid 44162669)
11. Akama T, Baker SJ, Zhang YK, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 2009; 19:2129-2132.
12. Seiradake E, Mao W, Hernandez V, et al. Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles. J Mol Biol 2009; 390:196-207.
13. Xia Y, Cao K, Zhou Y, et al. Synthesis and SAR of novel benzoxaboroles as a new class of [beta] -lactamase inhibitors. Bioorg Med Chem Lett 2011; 21:2533-2536.
14. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet 2010; 375:148-159.
15. Simarro PP, Jannin J, Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med 2008; 5:e55.
16. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Rec. 2006; 81:71-80.
17. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005; 21:508-512. (Pubitemid 41447021)
18. Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med 2009; 11:e31.
19. Ding D, Zhao Y, Meng Q, et al. Discovery of novel benzoxaborole-based potent antitrypanosomal agents. ACS Med Chem Lett 2010; 1:165-169.
20. Nare B, Wring S, Bacchi C, et al. Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of latestage central nervous system african trypanosomiasis. Antimicrob Agents Chemother 2010; 54:4379-4388.
21. Jennings FW, Whitelaw DD, Urquhart GM. The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy. Parasitology 1977; 75:143-153. (Pubitemid 8240436)
22. Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 2011; 5:e1151.
23. Enserink M. Malaria's drug miracle in danger. Science 2010; 328:844-846.
24. Zhang YK, Plattner JJ, Freund YR, et al. Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents. Bioorg Med Chem Lett 2011; 21:644-651.
25. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44:235-249. (Pubitemid 32239479)
26. Kerns EH, Di L. Multivariate pharmaceutical profiling for drug discovery. Curr Top Med Chem 2002; 2:87-98.
27. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001; 1:92-100. (Pubitemid 33586044)
28. Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527-2534.
29. Apt W. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Devel Ther 2010; 4:243-253.
30. Wilkinson SR, Bot C, Kelly JM, Hall BS. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med Chem 2011; 11:2072-2084.
31. Hall BS, Wu X, Hu L, Wilkinson SR. Exploiting the drug-activating properties of a novel trypanosomal nitroreductase. Antimicrob Agents Chemother 2010; 54:1193-1199.
32. Wilkinson SR, Taylor MC, Horn D, et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A 2008; 105:5022-5027. (Pubitemid 351738503)
33. Lepesheva GI, Hargrove TY, Anderson S, et al. Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem 2010; 285:25582-25590.
34. Urbina JA, Payares G, Sanoja C, et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003; 21:27-38. (Pubitemid 36043972)
35. Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 1996; 40:2592-2597. (Pubitemid 26367650)
36. Khong A, Kerfoot M, Botero A, et al. A stringent in vivo assay for evaluating the efficacy of novel compounds against Trypanosoma cruzi in mice. In: Proceedings of the 12th International Conference on Parasitology (ICOPA XII); Melbourne, Australia; 2010. www.anacor.com.
37. Heyman I, Ip E, Liu L, Maples KR. AN2728 preclinical studies demonstrate an acceptable safety profile for the topical treatment of psoriasis and atopic dermatitis. In: Proceedings of the 67th Annual Meeting of the American Academy of Dermatology; San Francisco; 2009. www.anacor.com.
38. Baker SJ, Ding CZ, Akama T, et al. Therapeutic potential of boron-containing compounds. Future Med Chem 2009; 1:1275-1288.
39. Zane LT, Shakib S, Milne R, et al. Safety, tolerability and pharmacokinetics of a novel gram-negative antimicrobial, GSK2251052, in healthy subjects. In: Proceedings of the 21st European Congress of Clinical Microbiology and Infectious Diseases; Milan, Italu; 2011. www.anacor.com.
40. Heyman I, Ip E, Liu L, et al. Preclinical toxicology of AN2728, a novel oxaborole in development for the topical treatment of psoriasis. In: Proceedings of the International Investigative Dermatology Conference; Kyoto, Japan; 2008. www.anacor.com.